New biopharma will start out with marketed angina drug, pivotal-stage anticoagulant and Phase II-stage antiarrhythmic
Companies to design and commercialize new Fc-engineered monoclonal and bi-specific antibody drugs using Zymeworks' EEFECT platform
Taiwanese firm projects completing Phase III trials with oral nemonoxacin in China and Taiwan during 2012.
Future T cell therapies with less side effects.
Ligand Pharmaceuticals could generate up to $533.8 million+ through partnership with Roivant, which will develop the Phase III-ready glucagon receptor antagonist LGD-6972
Agency says additional clinical safety information and the satisfactory resolution of manufacturing facility inspection deficiencies needed before the NDAs can be approved
Immunobiotics, small molecules that combine immunostimulatory agents and antbiotics, decrease the number of live gram-negative bacteria in human serum.
A nanoparticle-based toxin-detainment strategy is used to safely deliver non-disrupted pore-forming toxins for immune processing.
Companies will develop cancer and autoimmune disease treatments based on CAR-T and T cell receptor technologies over a 10-year period